Latest Health News
Multi-Country Cholera Outbreak Update #34
In January 2026, 16,912 new cholera and AWD cases reported across 19 countries in three WHO regions, down 6% from December 2025. African Region had the highest cases, followed by Eastern Mediterranean and South-East Asia, with 182 deaths, up 20%. No outbreaks in Western Pacific or Americas.
Rare Disease Day 2026 Highlights Breakthrough Therapies
Rare Disease Day 2026 celebrates advances like Waskyra, first gene therapy for Wiskott-Aldrich Syndrome. Kygevvi approved as first treatment for TK2 Deficiency, improving muscle and respiratory function in patients.
Forzinity gains approval for Barth Syndrome, and Fabhalta expands to rare kidney diseases.
Cancer Statistics 2026: Survival Rate Hits 70%
U.S. five-year cancer survival rate reaches 70% for 2015–2021, up from 49% in 1970s, driven by immunotherapy and targeted therapies. Metastatic melanoma survival improved from 16% to 35% via immune checkpoint inhibitors.
Gains most notable in advanced cancers previously untreatable.
Kygevvi: First FDA Approval for TK2 Deficiency
FDA approved Kygevvi (doxecitine and doxribtimine) for TK2 Deficiency, a rare mitochondrial disorder, aiding muscle and respiratory function. Developed by UCB, it's for adults and children symptomatic before age 12, first targeted treatment beyond supportive care.
Availability expected in U.S. early 2026.
Forzinity Approved for Barth Syndrome
Forzinity (elamipretide) received accelerated FDA approval in 2025 for Barth Syndrome, an ultra-rare X-linked mitochondrial disorder affecting males. It's the first disease-targeted treatment for this life-threatening cardiomyopathy and myopathy.
Fabhalta Expands to Rare Kidney Diseases
Novartis' Fabhalta (iptacopan), initially for PNH in 2023, now approved for rare kidney diseases, improving hemoglobin and reducing transfusions. Oral complement inhibitor marks rapid expansion across rare conditions.
Alhemo Offers Convenience for Hemophilia
Novo Nordisk’s Alhemo (concizumab-mtci) approved in 2024 for pediatric hemophilia A/B with inhibitors, aged 12+. First once-daily subcutaneous injection to reduce bleeding, replacing infusions.
Discovery Reduces Checkpoint Inhibitor Heart Risks
Cincinnati Children's finds blocking TNF signaling via TNFR2 prevents immune checkpoint inhibitor-induced myocarditis in mice, without losing anti-tumor effects. CD8 T cells produce TNF targeting heart cells; targeted blockade stops inflammation cycle.
Human trials needed for safety.
Quantum Science Advances to Hospital Diagnostics
UChicago researchers develop quantum sensors for precise imaging like tissue hypoxia in lung, heart, metabolic diseases, and cancer. Aims for patient-friendly tech like MRI to detect issues early.
Enables new views of cellular communication and disease.
Generative AI Speeds Medical Data Analysis
UCSF study shows generative AI analyzes medical data faster than human teams, aiding quick research pipelines for patient needs. Junior researchers completed experiments and journal submission in months.
Relieves data science bottlenecks.
Diatom Cell Engineering for Biofuels and Health Products
Western University breakthrough enables efficient DNA delivery into diatoms via electroporation after cell wall treatment, speeding genetic engineering. Potential for producing biofuels, medicines, vitamins directly.
Reduces research time significantly.
CRISPR Medicine Milestone with Eli Lilly
Scribe Therapeutics and Eli Lilly hit second development milestone in in vivo gene-editing for undisclosed programs. Advances CRISPR-based therapies toward clinical use.